3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Nasopharyngeal Carcinoma
14
Triple Negative Breast Neoplasms
12
Carcinoma, Non-Small-Cell Lung
10
Esophageal Squamous Cell Carcinoma
9
Breast Neoplasms
8
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Small Cell Lung Carcinoma
6
Neoplasms
6
Advanced Solid Tumor
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Recurrence
4
Carcinoma, Hepatocellular
4
Stomach Neoplasms
3
Solid Tumor
3
Neoplasm Metastasis
3
Liver Neoplasms
3
Carcinoma, Transitional Cell
3
Turcot syndrome
2
Sarcoma
2
Oropharyngeal Neoplasms
2
Nasopharyngeal Neoplasms
2
NSCLC
2
Muscle Invasive Bladder Cancer (MIBC)
2
Carcinoma, Squamous Cell
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
3
toripalimab
2
atezolizumab
2
Specimen Handling
2
Celecoxib
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
camrelizumab
1
avelumab
1
XELOX
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Interleukin-2
1
Induction Chemotherapy
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Diffusion Tensor Imaging
1
DNA Mismatch Repair
1
DEAE-Dextran
1
Cyclophosphamide
1
Colonoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Turcot syndrome
×
toripalimab
×
1 year
×
Clear all
NCT06903858
2026-05-22
PICC-3
Sun Yat-sen University
Phase 2
Recruiting
105 enrolled
NCT03926338
2025-11-20
PICC
Sun Yat-sen University
Phase 2
Recruiting
270 enrolled